Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Nov;22(5):527–534. doi: 10.1111/j.1365-2125.1986.tb02931.x

Pharmacodynamic and pharmacokinetic studies on bufuralol in man.

T H Pringle, R J Francis, P B East, R G Shanks
PMCID: PMC1401192  PMID: 2878678

Abstract

Observations were made in eight subjects who exercised before and at 1, 2, 4, 6, 8 and 24 h after the double-blind oral administration of placebo, bufuralol 7.5, 15, 30, 60 and 120 mg and propranolol 40 and 160 mg. The exercise heart rate remained constant after placebo. Bufuralol 7.5 mg and propranolol 40 mg reduced exercise heart rate up to 6 and 8 h respectively after dosing but bufuralol 15, 30, 60 and 120 mg and propranolol 160 mg were still active at 24 h. The lowest exercise heart rate occurred at 2 h after all active treatments. Bufuralol 60 and 120 mg produced similar reduction in exercise tachycardia as propranolol 40 mg but less than propranolol 160 mg. Plasma levels of bufuralol and its two major metabolites were measured. The peak plasma concentrations of bufuralol occurred at 1.5 h after 7.5 mg and at 2 h after the other doses of bufuralol. In six subjects the plasma elimination half-life of bufuralol was 2.61 +/- 0.18 h and in the other three subjects 4.85 +/- 0.35 h. There was a corresponding longer time to peak concentration and plasma elimination half-life of the two metabolites in these three subjects. These findings show that bufuralol is a potent beta-adrenoceptor antagonist with partial agonist activity. It has a long duration of action and there is bimodal metabolism of the drug in man.

Full text

PDF
527

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balant L., Gorgia A., Tschopp J. M., Revillard C., Fabre J. Pharmacocinétique de deux médicaments bêta-bloquants: détection d'une anomalie pharmacogénétique. Schweiz Med Wochenschr. 1976 Oct 9;106(41):1403–1407. [PubMed] [Google Scholar]
  2. Dayer P., Balant L., Courvoisier F., Kupfer A., Kubli A., Gorgia A., Fabre J. The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):73–77. doi: 10.1007/BF03189547. [DOI] [PubMed] [Google Scholar]
  3. Dayer P., Kubli A., Kupfer A., Courvoisier F., Balant L., Fabre J. Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol. 1982 May;13(5):750–752. doi: 10.1111/j.1365-2125.1982.tb01453.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eckert M., Cocco G., Strozzi C., Heizmann P., Sfrisi C. Relationship between pharmacokinetic and pharmacodynamic behaviour of bufuralol and its metabolite Ro 3-7410 in hypertensive patients. Eur J Clin Pharmacol. 1983;24(4):479–484. doi: 10.1007/BF00609890. [DOI] [PubMed] [Google Scholar]
  5. Fothergill G. A., Francis R. J., Hamilton T. C., Osbond J. M., Parkes M. W. Bufuralol, a new beta-adrenoceptor blocking agent. Experientia. 1975 Nov 15;31(11):1322–1323. doi: 10.1007/BF01945806. [DOI] [PubMed] [Google Scholar]
  6. Francis R. J., East P. B., McLaren S. J., Larman J. Determined of bufuralol and its metabolites in plasma by mass fragmentography and by gas chromatography with electron capture detection. Biomed Mass Spectrom. 1976 Dec;3(6):281–285. doi: 10.1002/bms.1200030606. [DOI] [PubMed] [Google Scholar]
  7. George C. F., Lewis P. J., Steiner J. A., Dollery C. T. A comparison of propranolol and compound RO3-4787 in the treatment of arterial hypertension in man. Clin Sci Mol Med Suppl. 1975 Jun;2:65s–67s. doi: 10.1042/cs048065s. [DOI] [PubMed] [Google Scholar]
  8. Hamilton T. C., Parkes M. W. Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: pharmacology. Arzneimittelforschung. 1977 Jul;27(7):1410–1417. [PubMed] [Google Scholar]
  9. Machin P. J., Hurst D. N., Osbond J. M. Beta-adrenoceptor activity of the stereoisomers of the bufuralol alcohol and ketone metabolites. J Med Chem. 1985 Nov;28(11):1648–1651. doi: 10.1021/jm00149a018. [DOI] [PubMed] [Google Scholar]
  10. Magometschnigg D., Bonelli J., Hitzenberger G., Kaik G., Korn A. Decrease of peripheral resistance after acute intravenous application of a new beta-receptor blocking agents, bufuralol HCl. Int J Clin Pharmacol Biopharm. 1978 Feb;16(2):54–58. [PubMed] [Google Scholar]
  11. Magometschnigg D., Bonelli J., Kaik G., Rameis H. Hemodynamic changes in hypertensive patients at rest and during physical exercise before and after acute i.v. administration of bufuralol-HCl or propranolol. Int J Clin Pharmacol Biopharm. 1979 Aug;17(8):334–340. [PubMed] [Google Scholar]
  12. McDevitt D. G. Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant? Drugs. 1983 Apr;25(4):331–338. doi: 10.2165/00003495-198325040-00001. [DOI] [PubMed] [Google Scholar]
  13. Minder E. I., Meier P. J., Müller H. K., Minder C., Meyer U. A. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation. Eur J Clin Invest. 1984 Jun;14(3):184–189. doi: 10.1111/j.1365-2362.1984.tb01121.x. [DOI] [PubMed] [Google Scholar]
  14. Pert C. B., Schumacher U. K. Plasma bombesin concentrations in patients with extensive small cell carcinoma of the lung. Lancet. 1982 Feb 27;1(8270):509–509. doi: 10.1016/s0140-6736(82)91478-7. [DOI] [PubMed] [Google Scholar]
  15. Pfisterer M., Burckhardt D., Bühler F. R., Burkart F. Acute hemodynamic effects of bufuralol: a beta-adrenoceptor blocking drug with vasodilatory effects. J Cardiovasc Pharmacol. 1984 May-Jun;6(3):417–422. doi: 10.1097/00005344-198405000-00007. [DOI] [PubMed] [Google Scholar]
  16. Tschopp J. M., Gorgia A., Balant L., Revillard C., Francis R. J., Fabre F. J. Rôle des métabolites dans les relations entre la pharmacocinétique et l'effet des agents beta-bloquants. Expériences avec le tolamolol et le bufuralol. Schweiz Med Wochenschr. 1978 May 20;108(20):756–764. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES